<DOC>
	<DOCNO>NCT01627795</DOCNO>
	<brief_summary>Malignant mesothelioma rare neoplasm arise commonly mesothelial surface pleural cavity , occasionally peritoneal surface , rarely tunica vaginalis pericardium . It extremely poor prognosis median survival 4 13 month untreated patient 1 6 18 month treat patient , regardless therapeutic approach . The anticancer activity Oshadi D Oshadi R treatment test preclinical study phase I clinical study . Four metastatic mesothelioma patient treat 5 12 month . The Oshadi D Oshadi R combination treatment generally well-tolerated dose-limiting toxicity observe .</brief_summary>
	<brief_title>Safety Efficacy Oshadi D Oshadi R Malignant Mesothelioma Treatment</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>Histologically cytologically proven diagnosis malignant mesothelioma Man woman 21 year Adequate performance status ( ECOG 0 , 1 , 2 ) Patient must adequate organ function follow : Absolute neutrophils count ( ANS ) &gt; 2500/μL . Platelets &gt; 150,000/μL . Hemoglobin &gt; 10 g/dL . Total Bilirubin &lt; 1.5 Upper Normal Limit ( UNL ) . Alanine aminotransferase ( ALT ) , AST ( aspartate aminotransferase ) alkaline phosphatase must &lt; 1.5 time upper limit normal . LDH ( lactate dehydrogenase ) &lt; 500 int . unit/L Estimated GFR ( glomerular filtration rate ) &gt; 45 ml/min . Written inform consent Females childbearing potential male must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) time consent sign 6 week treatment discontinuation . Females childbearing potential must negative pregnancy test within 7 day prior register protocol therapy . Evidence liver metastasis Any bone involvement Prior radiotherapy , cytotoxic biologic systemic treatment Any history Asthma COPD ( chronic obstructive pulmonary disease ) need systemic therapy steroid 2 week last 2 year . Treatment systemic steroid 1 month last year . Active smoker unable quite smoke Any treatment investigational agent within 30 day prior registration protocol therapy . Cerebrovascular accident , transient ischemic attack myocardial infarction within 6 month prior registration protocol therapy . Evidence pulmonary embolism within 6 month prior registration protocol therapy . Any history solid hematologic malignancy . Patient positive HIV serology screen . Female patient breastfeed positive pregnancy test screening time study . Uncontrolled hypertension ( &gt; 150/100 mm Hg despite optimal medical therapy ) . Evidence ongoing cardiac dysrhythmias NCI CTCAE ( Common Toxicity Criteria Adverse Effects ) Version 3.0 grade 2 . Patients radiation surgery indicate Significant swallow disorder . Small bowel surgery . Suspicion absorption disruption result abdominal radiation Preexisting malabsorption syndrome , irritable bowel syndrome clinical situation could affect oral absorption . Evidence concurrent ( &lt; 5 year ) second malignancy Mental disorder . Inability give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Malignant Mesothelioma</keyword>
	<keyword>Cancer</keyword>
	<keyword>Anti cancer agent</keyword>
</DOC>